The low-molecular weight heparin nadroparin calcium is used clinically for the prevention and treatment of venous and arterial thrombosis. The antifactor Xa and antifactor IIa assays were validated by investigating the parameters of range, linearity (r2 = 0.9905 and r2 = 0.9914, respectively) precision, accuracy, and robustness. The 2 methods incorporated a chromogenic endpoint and detection at 405 nm, yielding good results with detection limits of 0.004 and 0.01 IU/mL and quantitation limits of 0.01 and 0.03 IU/mL, respectively, for the antifactor Xa and antifactor IIa assays. Nadroparin calcium pharmaceutical products were evaluated by the antifactor Xa assay and the antifactor IIa assay, giving potencies between 93.86 and 109.88%, with an antifactor Xa/antifactor IIa ratio between 3.2 and 3.7. The results demonstrated the validity of the assays that are useful methodologies for the routine quality control of nadroparin in pharmaceutical formulations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Enoxaparin sodium is a low molecular mass heparin essential for effective anticoagulation therapy. However, significant variations in testing methods across different manufacturers have led to poor reproducibility of results, increasing the risks associated with drug quality evaluation by manufacturers and regulatory oversight. This study integrates the strengths of various testing methods to establish a reproducible assay that has been thoroughly validated.
View Article and Find Full Text PDFEstablishment and Validation of an Automated System for the Antifactor IIa Assay: A Case Study of Potency Assessment of a Pharmaceutical Gel Formulation.
ACS Omega
April 2024
Faculty of Pharmacy, Department of Biochemistry, Ege University, Bornova, Izmir 35040, Türkiye.
Antithrombotic agents and anticoagulant drugs, such as those from the heparin family, are employed in clinical settings for the prevention and treatment of clotting, thromboembolism, and wound healing. The potency assessment of antithrombotic agents is typically conducted using antifactor IIa assay with manual systems which are time-consuming and often lack repeatability. Here, we present a novel automated system that significantly enhances assay repeatability, attaining an outstandingly low relative standard deviation (RSD) % of only 0.
View Article and Find Full Text PDFChromogenic and Clot-Based Bivalirudin Assays for Monitoring Anticoagulation.
J Appl Lab Med
November 2023
Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, United States.
Background: Direct thrombin inhibitors (DTIs) are usually monitored with the activated partial thromboplastin time (aPTT) or activated clotting time (ACT). Both are complex assays with multiple enzymatic steps, and performance may be influenced by physiologic and pathologic factors unrelated to the DTI. Simpler systems, such as clot-based dilute thrombin time (dTT) and chromogenic anti-factor IIa assays, have been developed for monitoring DTIs, but there is limited data on their performance in clinical settings.
View Article and Find Full Text PDFPopulation pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation.
Front Cardiovasc Med
October 2022
Department of Pharmacy, Peking University First Hospital, Beijing, China.
Article Synopsis
- The study developed a pharmacokinetic (PK) and pharmacodynamic (PD) model using data from healthy Chinese individuals and non-valvular atrial fibrillation (NVAF) patients to understand bleeding risks and drug effects.* -
- The model utilized extensive data including dabigatran concentration and various coagulation tests from 285 participants, revealing strong correlations between PD biomarkers and bleeding events over a year.* -
- Key findings indicated that fixed dabigatran doses could be safely administered to NVAF patients without adjusting for certain factors, while higher exposure levels correlated with increased bleeding risk, necessitating further randomized studies for efficacy in this population.*
Deaminative-cleaved S. monotuberculatus fucosylated glycosaminoglycan: Structural elucidation and anticoagulant activity.
Carbohydr Polym
December 2022
Institute of Marine Drugs, Guangxi University of Chinese Medicine, Nanning 530200, China. Electronic address:
Stichopus monotuberculatus is a tropical sea cucumber species and used as a folk medicine and tonic food. In this study, a fucosylated glycosaminoglycan (SmFG), the depolymerized SmFG (dSmFG) and its oligosaccharide fractions were prepared. The SmFG and its depolymerized products were comprised of a chondroitin-sulfate-E backbone, and various sulfated fucose side chains, including an unusual disaccharide side chain connected to the C-3 position of D-glucuronic acid (GlcA) or GlcA-ol.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!